Amgen to Acquire Onyx Pharmaceuticals For $125/Share In Cash

Amgen AMGN and Onyx Pharmaceuticals, Inc. ONXX today announced that their Boards of Directors have unanimously approved a transaction under which Amgen will acquire all of the outstanding shares of Onyx for $125 per share in cash.  The purchase price is $10.4 billion, or $9.7 billion net of estimated Onyx cash.  Onyx Pharmaceuticals, Inc. is a global biopharmaceutical company engaged in the development and commercialization of innovative therapies for improving the lives of people with cancer.  Onyx has an important and growing multiple myeloma franchise, with Kyprolis® (carfilzomib) for Injection already approved in the United States (U.S.). In addition, Onyx has three partnered oncology assets: Nexavar® (sorafenib) tablets (an Onyx and Bayer HealthCare Pharmaceuticals, Inc. compound), Stivarga® (regorafenib) tablets (a Bayer compound), and palbociclib (a Pfizer, Inc. compound).  Onyx also has multiple oncology compounds in various stages of clinical development. Amgen See full press release
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsGuidanceContractsAsset SalesManagementM&AGlobal
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!